Related Experiment Video
Updated: Jun 19, 2026
11:36
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Methyldopa-induced autoimmune haemolytic anaemia revisited
Anish Thomas1, Bridget R James, Stephen L Graziano
1Department of Medicine, SUNY Upstate Medical University, Syracuse, NY-13202, USA. thomasan@upstate.edu
The New Zealand Medical Journal
|October 16, 2009
Summary
Methyldopa-induced immune hemolytic anemia is rare but can be missed. This case highlights unique diagnostic challenges and mechanisms of drug-induced hemolysis.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Drug-induced hemolytic anemia (DIHA) is a significant clinical concern.
- Methyldopa was historically a leading cause of DIHA but is now infrequently used.
- Immune-mediated hemolysis presents diagnostic challenges, particularly when drug-induced.
Observation:
- A young woman presented with initially missed diagnosis of methyldopa-induced immune hemolytic anemia.
- The case underscores the importance of considering drug-induced mechanisms even with rare etiologies.
- Specific diagnostic features of methyldopa-induced hemolysis were noted.
Findings:
- The patient developed immune hemolytic anemia attributed to methyldopa exposure.
- Diagnostic workup revealed characteristic serological findings consistent with drug-induced antibodies.
- Understanding the mechanisms of drug-induced immune hemolysis is crucial for accurate diagnosis.
Implications:
- This case emphasizes the need for heightened clinical suspicion for DIHA, including methyldopa-induced cases.
- Early recognition and withdrawal of the offending drug are critical for patient management.
- Further research into the unique immunopathogenesis of methyldopa-induced hemolysis may improve diagnostic strategies.
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:01Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:27Disorders of Erythrocytes
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...